Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091507 · ClinicalTrials.gov registry record · Phase 3
IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
A Phase 3 study of Cardiovascular Diseases and Heart Diseases, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 911
- Enrollment target
- 13
- Study locations
NCT00091507 is a Phase 3 study of Cardiovascular Diseases and Heart Diseases that has completed, run by Tufts Medical Center. The registered enrollment target is 911 participants, below the 26,971-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (97% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT00091507, a Phase 3 study of Cardiovascular Diseases and Heart Diseases, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 911 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to test the impact of pharmacological myocardial metabolic support, in the form of intravenous (IV) glucose, insulin and potassium (GIK), for the treatment of patients with threatened or established acute myocardial infarction (AMI).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GIK
Study Locations (13)
Massachusetts
- Brockton Site - Brockton
- Concord Site - Concord
Texas
- Dallas Site - Dallas
- El Paso Site - El Paso
Alaska
- Anchorage Site - Anchorage
Connecticut
- New Haven Site - New Haven
Georgia
- Macon Site - Macon
Minnesota
- St. Paul Site - Saint Paul
New Mexico
- Albuquerque Site - Albuquerque
Pennsylvania
- Hershey Site - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 911 participants |
| Start Date | 2006-11 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091507
The ClinicalTrials.gov registry entry for NCT00091507 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 911 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,971-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (97% lower). The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00091507 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Massachusetts, Texas, Alaska.
Frequently Asked Questions
What is clinical trial NCT00091507 about?
NCT00091507 is a clinical study titled "IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.". The purpose of this study is to test the impact of pharmacological myocardial metabolic support, in the form of intravenous (IV) glucose, insulin and potassium (GIK), for the treatment of patients with threatened or established acute myocardial infarction (AMI).
What is the current status of trial NCT00091507?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 911 participants. The study started on 2006-11. Estimated completion is 2012-08.
What conditions does trial NCT00091507 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Coronary Disease, Heart Failure, Congestive.
What interventions are being tested in trial NCT00091507?
The interventions under investigation include: Placebo (DRUG), GIK (DRUG).
Who is sponsoring clinical trial NCT00091507?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00091507 being conducted?
This trial has 13 study locations across Alaska, Connecticut, Georgia, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Cardiovascular Effects of a Healthy Dietary Pattern Containing Eggs
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
ACTIVE NOT RECRUITING · Phase 3
-
Comparison of Hematocrit Levels in Infant Heart Surgery
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.